Remove Download Remove Trials Remove Vaccine
article thumbnail

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

The Pharma Data

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif.

Vaccine 52
article thumbnail

Seven Strategies to Avoid Common Pitfalls in Vaccine Development

PPD

Clinical trials for COVID-19 vaccines changed how all vaccine trials are conducted. The success of the COVID-19 vaccines has brought renewed interest to vaccine development across indications and therapeutic areas. With so much at stake, don’t leave your vaccine development to chance.

Vaccine 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet

The Pharma Data

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. The phase 1 clinical trial was a randomized, double-blind and placebo-controlled study in 150 adult and elderly participants.

article thumbnail

Keeping tabs on Covid-19: UK firm tests oral delivery of Covid-19 vaccine and Novavax aims to distribute 51 million vaccines to Australia

The Pharma Data

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52
article thumbnail

Cytiva supports Clover Biopharmaceuticals to scale up the output of its vaccine candidate

The Pharma Data

Clover aims to double its commercial manufacturing capacity in preparation for global Phase 2/3 trials. In addition, this will meet Clover’s Phase 2/3 clinical production plan and commercial readiness once its vaccine candidate is approved. SHANGHAI , Nov. SHANGHAI , Nov.

Vaccine 52
article thumbnail

Johnson & Johnson Statement on COVID-19 Vaccine (7/12)

The Pharma Data

Rare cases of the neurological disorder, Guillain-Barré syndrome have been reported following vaccination with the Janssen COVID-19 vaccine. Most occurred within 42 days after vaccination. For further information on the safety of authorized COVID-19 vaccines, please visit: [link]. What Is the Janssen COVID-19 Vaccine?

Vaccine 52
article thumbnail

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate

The Pharma Data

First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S. Johnson & Johnson will develop and test its COVID-19 vaccine candidate in accordance with high ethical standards and sound scientific principles.